rao et al; phenome-wide association study of pcsk9 variants
Published 5 years ago • 274 plays • Length 5:22Download video MP4
Download video MP3
Similar videos
-
6:08
van der laan et al; cvd risk loci and plaque subphenotypes
-
2:31
what are pcsk9 inhibitors? (new lipid lowering drugs)
-
23:18
professor kausik ray - pcsk9 inhibition – have we reached the limits of lipid lowering and outcome?
-
35:58
professor rodrigo alonso - have we reached the limits of lipid lowering and outcome?
-
2:40
pcsk9 inhibitors explained in 3 minutes
-
19:22
repatha
-
13:57
innovative access solutions for complex pci - europcr 2022
-
4:18
reducing ldl by pcsk9 inhibitors repatha or praluent
-
17:23
lipidology
-
1:03
patient registry for people witih severe hypertriglyceridemia
-
4:21
hpc900 high pressure unit for panalytical xrds
-
1:05:30
pcsk9 inhibition: lowering lipids and reducing cardiovascular events
-
1:50
hyperreflective foci in dme
-
2:02
high lipoprotein(a) - a common condition that is rarely tested
-
2:52
ldl apheresis
-
54:46
tavr in lf-lg severe as and contractile reserve with evolut pro valve
-
3:41
cost-effectiveness of pcsk9 inhibitors for heterozygous fh or ascvd
-
7:55
normal renal arterial doppler - case study
-
4:23
cholesterol/hdl ratio is an important indicator of cardiovascular risk
-
46:19
lmp grand rounds rkaufmann 4nov2020
-
3:31
dr peter lansberg: what does fourier mean for fh patients?
-
39:02
evolving approaches to planning & guiding of complex pci with ultra-low contrast - aict-asiapcr 2022